ELIAS JOSEPH JABBOUR to Drug Monitoring
This is a "connection" page, showing publications ELIAS JOSEPH JABBOUR has written about Drug Monitoring.
Connection Strength
1.236
-
Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring. Am J Hematol. 2016 Feb; 91(2):252-65.
Score: 0.462
-
Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management. Am J Hematol. 2012 Nov; 87(11):1037-45.
Score: 0.369
-
Pro-adrenomedullin as a novel biomarker for predicting infections and response to antimicrobials in febrile patients with hematologic malignancies. Clin Infect Dis. 2013 Apr; 56(7):943-50.
Score: 0.093
-
Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Am J Hematol. 2012 Jul; 87(7):687-91.
Score: 0.088
-
Current perspectives on the treatment of patients with chronic myeloid leukemia: an individualized approach to treatment. Cancer J. 2007 Nov-Dec; 13(6):357-65.
Score: 0.065
-
Optimal first-line treatment of chronic myeloid leukemia. How to use imatinib and what role for newer drugs? Oncology (Williston Park). 2007 May; 21(6):653-62; discussion 663-4, 667-8.
Score: 0.063
-
Optimizing the use of the hyperCVAD regimen: Clinical vignettes and practical management. Cancer. 2020 03 15; 126(6):1152-1160.
Score: 0.038
-
A phase 1 study of AMG 900, an orally administered pan-aurora kinase inhibitor, in adult patients with acute myeloid leukemia. Am J Hematol. 2017 Jul; 92(7):660-667.
Score: 0.032
-
A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. Clin Cancer Res. 2015 Jun 15; 21(12):2704-14.
Score: 0.027